Okeiro raises €10 million to transform precision medicine in transplantation
Okeiro, a deeptech startup specializing in precision medicine applied to transplantation and chronic diseases, announces a €10 million financing round. This round of financing is led by Alven, Forepont Capital Partners and Red River West. This operation will enable the company to accelerate its deployment in France and Europe, with entry into the US market planned in the coming months.
Okeiro's platform, based on the iBox algorithm - a clinically validated biomarker recognized by the FDA and EMA - enables physicians to predict post-transplant complications and optimize patient follow-up. Already used in France's leading transplant centers and reimbursed by the French health insurance system, it has established itself as a breakthrough innovation, both for quality of care and for clinical research. This fundraising will also enable the development of new AI tools, aimed at improving diagnosis and personalizing treatments.
With a robust scientific foundation and AI models validated by rigorous clinical trials, Okeiro is committed to transforming transplant medicine on an international scale. Our ambition is to create a new paradigm of care, where technology enhances care, patient experience and clinical research.
Pierrick Arnal, CEO
With a clinical study underway in 16 hospitals across Europe and the Middle East, and a new, assertive identity - formerly Predict4Health - Okeiro aims to become a global reference in precision medicine, placing artificial intelligence at the heart of chronic disease monitoring.
ACL's teams supported Okeiro in this operation through their accounting services.accounting and consulting services.
